Do I need genetic testing while taking Lorlatinib?

Lorlatinib (Lorlatinib) is a targeted therapy drug used to treat ALK (tyrosine kinase) and ROS1 positive non-small cell lung cancer (NSCLC). Genetic testing plays a key role in lorlatinib treatment. The following will discuss in detail why genetic testing is crucial for lorlatinib treatment.

1. ConfirmALK or ROS1 mutation

First of all, the main purpose of genetic testing is to confirm whether the patient carries a mutation in the ALK or ROS1 gene. Lorlatinib is a highly targeted drug that works only against tumors with two specific genetic mutations. Therefore, patients must undergo genetic testing to ensure that their tumors are ALK or ROS1 positive.

2. Determine treatment plan

Once it is determined that the patient's tumor is ALK or ROS1 positive, the doctor can develop an individualized treatment plan based on the test results. Lorlatinib is often used as initial treatment or as an alternative treatment option. This decision is based on the patient's genotype, as well as possible treatment options.

3. Maximize efficacy

Genetic testing can help ensure patients receive the maximum benefit from treatment. The use of lorlatinib for ALK or ROS1 positive tumors can significantly improve the progression-free survival of patients (Progression-Free Survival, PFS) and extend the time of disease control.

4.Avoid unnecessary side effects

Genetic testing can also help doctors avoid prescribing lorlatinib to patients who are ALK or ROS1 negative, thereby reducing unnecessary drug exposure and the risk of side effects. This individualized approach to treatment helps maximize the safety and effectiveness of treatment.

5. Resistance Management

In some cases, patients may develop resistance to lorlatinib. Genetic testing can help doctors understand the mechanisms of drug resistance and adjust treatment options accordingly. This could include selecting other targeted therapies or participating in clinical trials.

6. Understand tumor characteristics

Through genetic testing, doctors can also gain a deeper understanding of the molecular characteristics of tumors. This helps predict disease progression and treatment response, providing patients with more comprehensive medical care.

In summary, genetic testing is very important for lorlatinib treatment. Not only does it ensure patients receive maximum treatment efficacy, it also avoids unnecessary drug exposure and the risk of side effects. Therefore, genetic testing should be standard clinical practice before initiating lorlatinib treatment to ensure optimal treatment outcomes for patients. This personalized treatment approach represents a major advance in modern cancer treatment and is expected to improve patients' survival rates and quality of life.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For details, please consult the local hospital pharmacy. There are original drugs and cheaper generic drugs abroad. The cheaper ones are the original drugs from Turkey, which cost more than 1,000 yuan, and the original drugs from Hong Kong, China, which cost about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.